Status:
RECRUITING
Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion
Lead Sponsor:
Centre Hospitalier Universitaire de la Réunion
Collaborating Sponsors:
ANRS, Emerging Infectious Diseases
Région La Réunion
Conditions:
Chikungunya Virus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals ...
Eligibility Criteria
Inclusion
- Eligible for anti-chikungunya vaccination according to french Health Authority (HAS)
- Beneficiary of social security coverage
- Signature of informed consent form
Exclusion
- Pregnant women
- Vaccine contraindication for patients undergoing medical treatment
- Persons under guardianship, curatorship or safeguard of justice
- Anyone who has received immunoglobulin or a blood or plasma transfusion 3 months prior to vaccine administration
Key Trial Info
Start Date :
April 18 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT06928753
Start Date
April 18 2025
End Date
October 1 2026
Last Update
July 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU La Réunion
Saint-Denis, France